{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-061435","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.091410+00:00","generated_at":"2026-05-18T23:26:43.865048+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ocugen's OrthoCellix to merge with Carisma in reverse merger; combined entity to focus on NeoCart","bullets":["OrthoCellix valued at $135M; Carisma at $15M; post-merger Ocugen/investors own ~90%, Carisma holders ~10%.","Concurrent $25M financing from Ocugen ($5M guaranteed) and other investors to fund NeoCart Phase 3 trial.","Combined company to trade as 'OrthoCellix Inc.' on Nasdaq under ticker OCLX; closing expected H2 2025.","NeoCart is Phase 3-ready autologous cartilage implant for knee defects; received FDA RMAT designation.","Carisma legacy asset CVRs issued to pre-merger Carisma stockholders; termination fees of $500K-$750K if deal fails."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-061435","json":"https://secwatch.observer/filing/0001104659-25-061435.json","markdown":"https://secwatch.observer/filing/0001104659-25-061435.md","text":"https://secwatch.observer/filing/0001104659-25-061435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925061435/0001104659-25-061435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925061435/tm2518642d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:26:43.865048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}